Leads Based Upon Schering Compounds. SPL shall not be obligated to disclose the structure of any Schering Compound(s) proposed as Lead Compounds unless and until Pharmacopeia has agreed, pursuant to Section 2.1.1, to conduct an Optimization Program against the relevant Target. Upon Pharmacopeia’s agreement to conduct an Optimization Program based upon one or more Lead Compounds which are Schering Compounds, SPL shall disclose to Pharmacopeia the structure of such Schering Compounds. Effective upon the date Pharmacopeia agrees to perform an Optimization Program based upon one or more Lead Compounds which are Schering Compounds, *for the period extending from
Appears in 3 contracts
Samples: Collaboration and License Agreement, Collaboration and License Agreement (Ligand Pharmaceuticals Inc), Collaboration and License Agreement (Pharmacopeia Inc)
Leads Based Upon Schering Compounds. SPL Schering shall not be obligated to disclose the structure of any Schering Compound(s) proposed as Lead Compounds unless and until Pharmacopeia has agreed, pursuant to Section 2.1.1, to conduct an Optimization Program against the relevant Target. Upon Pharmacopeia’s agreement to conduct an Optimization Program based upon one or more Lead Compounds which are Schering Compounds, SPL Schering shall disclose to Pharmacopeia the structure of such Schering Compounds. Effective upon the date Pharmacopeia agrees to perform an Optimization Program based upon one or more Lead Compounds which are Schering Compounds, *for the period extending fromfrom *
Appears in 2 contracts
Samples: Collaboration and License Agreement (Ligand Pharmaceuticals Inc), Collaboration and License Agreement (Pharmacopeia Inc)